Compare Healthcare Stocks

Compare Healthcare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., GILD, ABBV, BMY, CI) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$119.02 -0.9%	$111.59	$72.89 ▼ $121.83	$147.68B	0.33	8.36 million shs	5.46 million shs
ABBV AbbVie	$204.78 +1.6%	$190.39	$163.81 ▼ $218.66	$361.75B	0.5	6.73 million shs	4.63 million shs
BMY Bristol Myers Squibb	$47.86 +0.0%	$47.23	$42.96 ▼ $63.33	$97.42B	0.36	13.40 million shs	9.41 million shs
CI Cigna Group	$290.55 +1.2%	$302.73	$256.89 ▼ $370.83	$77.56B	0.47	1.85 million shs	1.99 million shs
JNJ Johnson & Johnson	$174.96 +0.3%	$160.42	$140.68 ▼ $175.72	$421.37B	0.41	9.04 million shs	8.24 million shs
LLY Eli Lilly and Company	$685.27 +3.8%	$767.52	$623.78 ▼ $972.53	$625.13B	0.44	4.14 million shs	8.34 million shs
MDT Medtronic	$92.04 -0.9%	$89.11	$79.29 ▼ $96.25	$117.97B	0.8	7.63 million shs	6.85 million shs
MRK Merck & Co., Inc.	$82.77 +0.1%	$80.97	$73.31 ▼ $120.30	$206.75B	0.38	15.55 million shs	10.21 million shs
PFE Pfizer	$25.12 -0.2%	$24.52	$20.92 ▼ $30.43	$142.79B	0.52	45.76 million shs	32.46 million shs
UNH UnitedHealth Group	$271.79 0.0%	$289.37	$234.60 ▼ $630.73	$246.17B	0.43	12.21 million shs	22.35 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	+0.10%	+8.94%	+7.18%	+19.73%	+62.40%
ABBV AbbVie	+1.41%	+2.54%	+5.13%	+10.93%	+5.30%
BMY Bristol Myers Squibb	+2.86%	+6.68%	+0.97%	+4.59%	-2.59%
CI Cigna Group	+2.20%	+6.26%	-5.27%	-6.97%	-13.75%
JNJ Johnson & Johnson	+0.87%	+2.09%	+11.07%	+16.66%	+10.04%
LLY Eli Lilly and Company	+3.27%	-11.49%	-17.40%	-9.83%	-27.26%
MDT Medtronic	+0.87%	+3.96%	+3.53%	+8.06%	+12.91%
MRK Merck & Co., Inc.	+2.96%	+4.11%	-1.25%	+10.70%	-27.73%
PFE Pfizer	+2.05%	+4.98%	-0.85%	+11.39%	-12.86%
UNH UnitedHealth Group	+3.95%	+10.72%	-9.47%	-0.74%	-52.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	4.586 of 5 stars	1.4	3.0	4.2	4.1	2.9	2.5	2.5
ABBV AbbVie	4.7517 of 5 stars	2.5	4.0	3.3	3.9	4.0	2.5	1.3
BMY Bristol Myers Squibb	4.7084 of 5 stars	2.1	4.0	4.2	4.0	3.5	2.5	1.3
CI Cigna Group	5 of 5 stars	4.5	4.0	3.3	4.2	4.2	1.7	3.8
JNJ Johnson & Johnson	4.7069 of 5 stars	2.3	3.0	4.2	3.9	3.7	1.7	1.9
LLY Eli Lilly and Company	4.9985 of 5 stars	4.3	4.0	3.3	4.0	3.2	3.3	3.1
MDT Medtronic	4.6946 of 5 stars	2.3	3.0	3.3	4.1	4.2	1.7	1.9
MRK Merck & Co., Inc.	4.9949 of 5 stars	3.2	5.0	5.0	4.2	3.1	1.7	3.8
PFE Pfizer	4.9897 of 5 stars	3.2	5.0	4.2	4.5	3.2	1.7	3.1
UNH UnitedHealth Group	4.9941 of 5 stars	4.3	3.0	4.2	4.0	3.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.80	Moderate Buy	$114.82	-3.84% Downside
ABBV AbbVie	2.93	Moderate Buy	$214.95	5.04% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	17.56% Upside
CI Cigna Group	3.00	Buy	$378.33	30.19% Upside
JNJ Johnson & Johnson	2.65	Moderate Buy	$174.50	-0.64% Downside
LLY Eli Lilly and Company	2.65	Moderate Buy	$964.88	41.26% Upside
MDT Medtronic	2.59	Moderate Buy	$98.19	6.67% Upside
MRK Merck & Co., Inc.	2.35	Hold	$107.44	29.64% Upside
PFE Pfizer	2.39	Hold	$28.12	11.69% Upside
UNH UnitedHealth Group	2.50	Moderate Buy	$366.52	34.93% Upside

Current Analyst Ratings Breakdown

Latest Healthcare Stocks Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	CI Cigna Group	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$372.00
8/14/2025	CI Cigna Group	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$362.00 ➝ $374.00
8/14/2025	CI Cigna Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$341.00 ➝ $340.00
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $98.00
8/8/2025	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$108.00 ➝ $112.00
8/8/2025	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$28.75B	5.15	$6.83 per share	17.47	$15.79 per share	7.56
ABBV AbbVie	$56.33B	6.42	$15.39 per share	13.30	($0.08) per share	-2,557.95
BMY Bristol Myers Squibb	$47.70B	2.05	$6.06 per share	7.91	$8.59 per share	5.58
CI Cigna Group	$247.12B	0.31	$39.16 per share	7.42	$151.46 per share	1.92
JNJ Johnson & Johnson	$88.82B	4.76	$13.34 per share	13.17	$32.58 per share	5.39
LLY Eli Lilly and Company	$45.04B	14.35	$15.21 per share	44.92	$19.39 per share	35.23
MDT Medtronic	$33.54B	3.52	$7.75 per share	11.88	$37.62 per share	2.45
MRK Merck & Co., Inc.	$64.17B	3.23	$9.77 per share	8.48	$19.64 per share	4.22
PFE Pfizer	$63.83B	2.24	$4.46 per share	5.65	$15.66 per share	1.61
UNH UnitedHealth Group	$400.28B	0.61	$33.62 per share	8.08	$110.93 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$480M	$5.02	23.80	14.72	0.75	21.86%	50.99%	17.24%	N/A
ABBV AbbVie	$4.28B	$2.10	97.45	14.64	1.28	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.32	7.87	2.38	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
CI Cigna Group	$3.43B	$18.32	15.87	8.80	0.82	1.92%	18.80%	5.02%	10/30/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	18.79	15.86	2.20	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	44.62	21.95	0.90	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
MDT Medtronic	$4.66B	$3.62	25.44	15.79	2.39	13.90%	14.54%	7.83%	8/19/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.76	8.37	0.85	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.38	8.31	0.88	16.84%	21.42%	9.12%	N/A
UNH UnitedHealth Group	$14.41B	$23.08	11.75	8.18	1.69	5.04%	23.32%	7.66%	10/21/2025 (Estimated)

Latest Healthcare Stocks Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q1 2026	MDT Medtronic	$1.23	N/A	N/A	N/A	$8.37 billion	N/A
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/31/2025	Q2 2025	CI Cigna Group	$7.15	$7.20	+$0.05	$5.71	$62.61 billion	$67.13 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/29/2025	Q2 2025	UNH UnitedHealth Group	$4.45	$4.08	-$0.37	$3.74	$111.75 billion	$111.62 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.16	2.65%	N/A	62.95%	10 Years
ABBV AbbVie	$6.56	3.21%	N/A	312.38%	53 Years
BMY Bristol Myers Squibb	$2.48	5.17%	N/A	100.00%	17 Years
CI Cigna Group	$6.04	2.08%	N/A	32.97%	5 Years
JNJ Johnson & Johnson	$5.20	2.96%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.88%	N/A	39.22%	11 Years
MDT Medtronic	$2.84	3.09%	N/A	78.45%	49 Years
MRK Merck & Co., Inc.	$3.24	3.91%	N/A	49.92%	14 Years
PFE Pfizer	$1.72	6.83%	N/A	91.49%	16 Years
UNH UnitedHealth Group	$8.84	3.25%	N/A	38.30%	15 Years

Latest Healthcare Stocks Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.97%	9/15/2025	9/15/2025	10/7/2025
8/8/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025
8/13/2025	UNH UnitedHealth Group	quarterly	$2.21	3.38%		9/15/2025	9/23/2025
7/22/2025	CI Cigna Group	quarterly	$1.51	2.01%	9/4/2025	9/4/2025	9/18/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.13	1.32	1.15
ABBV AbbVie	44.14	0.74	0.61
BMY Bristol Myers Squibb	2.54	1.21	1.11
CI Cigna Group	0.65	0.71	0.71
JNJ Johnson & Johnson	0.50	1.01	0.76
LLY Eli Lilly and Company	1.86	1.28	1.00
MDT Medtronic	0.53	1.85	1.42
MRK Merck & Co., Inc.	0.69	1.42	1.17
PFE Pfizer	0.65	1.16	0.85
UNH UnitedHealth Group	0.73	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
CI Cigna Group	86.99%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
UNH UnitedHealth Group	87.86%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.27%
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
CI Cigna Group	0.70%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
MDT Medtronic	0.20%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%
UNH UnitedHealth Group	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CI Cigna Group	73,500	266.93 million	265.06 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.49 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
UNH UnitedHealth Group	400,000	905.67 million	904.60 million	Optionable

Healthcare Stocks Headlines

Recent News About These Companies

UnitedHealth, Amedisys Deal Is Done, But Its Impact On Home Health Just Starting

2 hours ago | homehealthcarenews.comH

Warren Buffett Bets On Nucor, UnitedHealth, Housing; Apple Stake Pared

2 hours ago | msn.com

UnitedHealth Group (UNH) Board Affirms US$2.21 Dividend for September 2025

2 hours ago | finance.yahoo.com

Berkshire invests in UnitedHealth, trims Apple stake

2 hours ago | reuters.com

Warren Buffett's Berkshire announces surprise stake in embattled UnitedHealth

3 hours ago | nypost.comN

Warren Buffett’s New Mystery Stocks Is… UnitedHealth Group (UNH)

3 hours ago | tipranks.com

Warren Buffett's Berkshire Hathaway reveals new stake in beleaguered insurer UnitedHealth

3 hours ago | cnbc.com

Buffett's Berkshire acquires 5 million shares in UnitedHealth

3 hours ago | reuters.com

UnitedHealth Group (UNH) Faces Major Data Breach Impacting Millions

4 hours ago | gurufocus.com

Should You Buy The Dip On These Large-Cap 'Left-Behind' Stocks Like UnitedHealth And The Trade Desk?

4 hours ago | benzinga.com

Hack at UnitedHealth's tech unit impacted 192.7 million people

August 14 at 1:50 PM | reuters.com

UnitedHealth Group: Dividends Don't Lie

August 14 at 12:57 PM | seekingalpha.com

Wall Street Sees Long-Term Upside in UnitedHealth Group Stock (UNH) Despite Ongoing Challenges

August 14 at 12:13 PM | msn.com

Azimuth Capital Investment Management LLC Cuts Position in UnitedHealth Group Incorporated (NYSE:UNH)

August 14 at 8:46 AM | marketbeat.com

Why I Bought the Dip in UnitedHealth Group

August 14 at 8:04 AM | fool.com

Kovitz Investment Group Partners LLC Boosts Stake in UnitedHealth Group Incorporated (NYSE:UNH)

August 14 at 8:04 AM | marketbeat.com

What is Zacks Research's Forecast for UNH Q3 Earnings?

August 14 at 7:58 AM | marketbeat.com

Oak Ridge Investments LLC Increases Stock Position in UnitedHealth Group Incorporated (NYSE:UNH)

August 14 at 7:53 AM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) Shares Sold by Lord Abbett & CO. LLC

August 14 at 7:39 AM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) is Fjarde AP Fonden Fourth Swedish National Pension Fund's 10th Largest Position

August 14 at 7:13 AM | marketbeat.com

Mitsubishi UFJ Asset Management UK Ltd. Reduces Stock Position in UnitedHealth Group Incorporated (NYSE:UNH)

August 14 at 7:12 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Healthcare Stocks Company Descriptions

Gilead Sciences NASDAQ:GILD

$119.02 -1.12 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$119.35 +0.33 (+0.28%)

As of 06:34 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

AbbVie NYSE:ABBV

$204.78 +3.31 (+1.64%)

Closing price 03:59 PM Eastern

Extended Trading

$204.70 -0.08 (-0.04%)

As of 06:49 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$47.86 +0.01 (+0.03%)

Closing price 03:59 PM Eastern

Extended Trading

$47.86 -0.01 (-0.02%)

As of 06:48 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Cigna Group NYSE:CI

$290.55 +3.45 (+1.20%)

Closing price 03:59 PM Eastern

Extended Trading

$296.65 +6.11 (+2.10%)

As of 06:52 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Johnson & Johnson NYSE:JNJ

$174.96 +0.54 (+0.31%)

Closing price 03:59 PM Eastern

Extended Trading

$175.42 +0.45 (+0.26%)

As of 06:51 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$685.27 +24.78 (+3.75%)

Closing price 03:59 PM Eastern

Extended Trading

$693.06 +7.79 (+1.14%)

As of 06:53 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$92.04 -0.87 (-0.94%)

Closing price 03:59 PM Eastern

Extended Trading

$92.00 -0.04 (-0.05%)

As of 06:33 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Merck & Co., Inc. NYSE:MRK

$82.77 +0.06 (+0.08%)

Closing price 03:59 PM Eastern

Extended Trading

$82.97 +0.20 (+0.24%)

As of 06:52 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.12 -0.05 (-0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$25.08 -0.04 (-0.16%)

As of 06:52 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UnitedHealth Group NYSE:UNH

$271.79 -0.02 (-0.01%)

Closing price 03:59 PM Eastern

Extended Trading

$298.94 +27.15 (+9.99%)

As of 06:53 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Healthcare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest Healthcare Stocks Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest Healthcare Stocks Earnings

Compare Dividends

Latest Healthcare Stocks Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

Healthcare Stocks Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Healthcare Stocks Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools